

Impact Report • 2021-2022

LEADERSHIP

at the service of cancer **R**ESearch



.....

Research is the key
to outsmart cancer

.....



The Cancer Research Society is a recognized leader in the Canadian research sector, offering essential financial support to brilliant researchers across the country.



- *Manon Pepin, President and Chief Executive Officer, Cancer Research Society*

Summary

A message from the
President and Chief
Executive Officer

4

A message from the
Chair of the Board
of Directors

6

THE CANCER RESEARCH SOCIETY

A Canadian leader
in cancer research

8

Who are we?

10

Mission, vision
and values

10

Board of Directors

11

RESEARCH

Supporting Cancer
Research

13

Supporting the
Scientific Community

15

Peer-Review Process

17

Leveraging
our Impact

18

Partners

19

Impactful Results

20

Focus on
Researchers

22

FUNDRAISERS AND MOBILIZATION

26

DONORS

Types of donations

33

Donor portraits

35

Donors

36

FINANCIAL INFORMATION

41

COMMITMENT TO OUR DONORS

44

FUTURE GOALS

46

*This impact report presents the
Cancer Research Society's activities
and financial information for the
period from September 1, 2021
to August 31, 2022.*

A Message from the President and Chief Executive Officer

Cance**R** **R**esear**R**ch: St**R**ong Leade**R**ship

It is with great pleasure that we present to you our 2021-2022 Impact Report. The Cancer Research Society (CRS) had an exceptional year, once again positioning itself as a leader in philanthropic funding for cancer research in Canada. As a key player in the Canadian ecosystem, we are very proud of how far we have come over the past 75 years in our efforts to prevent, detect and treat cancer through research.



Funding for Research Projects: A Historical High

For 2021-2022, 181 research projects, including grants and scholarships, received funding from the CRS. Despite challenging conditions in the past year due to the COVID-19 pandemic, global inflation, sluggish capital market conditions and a shifting labour market, the CRS stayed the course and funded the largest number of research projects in its history.

The CRS also sets itself apart through its scholarship program, the only one of its kind in Canada, which offers financial support to the next generation of scientists at the postdoctoral level. These scholarships facilitate the transition to a position in a Canadian university or research centre. This program is crucial for encouraging the next generation of researchers to pursue their career in the Canadian cancer research sector.

Measurable Impact

This year, 104 new projects, including 4 scholarships for a total of \$14.4 million, will be awarded over the next 2 to 4 years depending on the type of project.

The growing number of investments we make is a strong confirmation of the impact that we have in Canadian cancer research as we fully intend to build on this momentum in spite of the unfavourable economic environment and workforce challenges.

Acknowledgements

First of all, an enormous thank you to all of the donors who contribute to outsmarting cancer by focusing on research.

The success of our mission is also largely due to the recommendations made by the members of our Scientific Advisory Committee. Furthermore, our partnership with other foundations and the Canadian Institutes of Health Research are at the core of our business model, which has allowed us to reach new heights.

These achievements would not have been possible without the organizing committees for our fundraising events and the corporate partners who invest in cancer research along with us. You are true partners on the road to success and we extend to you our heartfelt recognition.

We would also like to highlight the exceptional contribution made by close to 100 researchers and doctors who volunteer their time to evaluate the hundreds of research proposals that we receive. This is a rigorous, demanding process that they execute with rigor and integrity. We thank you for sharing your expertise with the CRS.

We must also mention the significant contribution made by our outgoing Chairman of the Board, Mr. François Painchaud, who will continue to serve our organization as a Board Member. Mr. Painchaud has provided invaluable support during a challenging period due to the pandemic. The contribution of our Board had a significant impact on the advancement of cancer research. We are very fortunate to be able to rely on such dedicated and committed individuals in the philanthropic community. At the same time, we would like to offer –our heartfelt congratulations to Mr. Christian Paupe, who was appointed Chair of the Board of Directors in December 2021. His experience as a senior executive represents a valuable asset in the pursuit of our mission.


In closing, many thanks to all CRS team members for their commitment and dedication that help us outsmart cancer.

Happy reading!

Manon Pepin
President and Chief Executive Officer

Message from the Chair of the Board of Directors

Once again,
the CRS has
Raised the ba**R**
and exceeded
its ta**R**gets to
outsmar**R**t cance**R**



Mr. Paupe has over 25 years of experience in the telecom, media and financial services sectors. He is currently a Corporate Director and Investor. As a senior executive of public and private companies, he has acquired extensive experience in strategy and management, as well as a thorough knowledge of capital markets. Mr. Paupe holds an MBA from Harvard Business School and a Bachelor's degree from the Royal Military College in Saint-Jean.

We are very pleased to present the 2021-22 Impact Report of the Cancer Research Society. This report represents an impressive account of the research efforts undertaken by our stakeholders over the past year with a shared commitment to outsmarting cancer.

In our support role of our partners and employees of the CRS, I have come to appreciate how we have become a true leader in cancer research in Canada. In recent years, the CRS has awarded a record number of research grants to distinguished researchers across the country. We should also highlight the growing number of scientific partnerships as we work to bring together the key players in cancer research. Despite the lingering effects of the COVID-19 pandemic, our research initiatives have reached an all-time high.

New challenges for philanthropy

At this time, we must bear in mind the challenging global economic environment and the historically high inflation that are impacting both individuals and businesses. The current economic conditions pose a number of challenges. We believe that the post-pandemic economic environment may lead some donors and corporate partners to exercise greater caution in their spending.

To offset these trends, we will closely monitor the performance indicators of our strategic plan for the period 2022–2027, striving to create winning conditions in view of this uncertain future and its potential impact on our human capital and financial resources. To this end, the CRS has reviewed its internal processes to make them more efficient and less costly. We will also resolutely continue our shift to digital and review our fundraising strategies to adapt to demographic and technological developments.

The Cancer Research Society can set its sights high due to the efforts of many individuals and organizations. We extend our warmest thanks to our generous donors and the corporate and partner organizations that invest in the CRS and believe in our mission. We would also like to recognize the unique contributions of the members of the Scientific Advisory Committee chaired by Dr. Mark Basik, of the members of the peer review panels and of the volunteers involved in our fundraising events.

I also want to recognize the commitment of our colleagues on the CRS Board of Directors, who contribute their experience and dedication to support the advancement of cancer research in Canada. Thank you all!

In closing, we would like to express our gratitude to Manon Pepin, President and Chief Executive Officer of the CRS, to the senior leadership team and to all of our employees. Despite many obstacles brought on by the current environment, your vision and your achievements have positioned us for continuing success. We are highly confident of the positioning of the Cancer Research Society and the achievement of our long-term strategic and financial objectives.

Christian M. Paupe
Chair of the Board of Directors

The Cancer Research Society

A Canadian
leade® in cance®
Resea®ch



Over the years, the Cancer Research Society (CRS) has stood out as an undisputed leader in cancer research within the country.

100
researchers and
doctors participated
in the review
committees

181
research projects,
including grants and
scholarships,
received funding

\$355
million awarded
since 1945

During the COVID-19 pandemic, while several organizations were forced to put their fundraising program on hold, we were resolute and present for the scientific community, awarding a record number of grants and scholarships for cancer research. We stayed the course in spite of numerous constraints caused by the pandemic and the many ensuing operational challenges.

For 2021-2022, 181 cancer research projects, including grants and scholarships, were selected for funding by the CRS, ultimately hastening the pace of research.

To do so, we multiplied the number of partnerships with various organizations whose missions are to fund cancer research projects.

The CRS' excellent reputation also rests on our peer-review committees, composed of some 100 researchers and doctors who evaluate and critique the 400+ proposals we receive each year. In addition, our newly implemented online grant management platform has been praised by users.

The professionalism and dedication of our staff must also be highlighted.

Mission

Exclusively fund research on all types of cancer in order to prevent, detect and treat this illness.

Vision

Research is the key to outsmart cancer

77
years of
existence

31
employees devoted
to maximizing
benefits

Who are we?

Founded in 1945, the Cancer Research Society is one of the only Canadian organizations exclusively dedicated to research into all types of cancer. Since its inception, the CRS has supported thousands of researchers who have made significant advances in cancer prevention, detection and treatment.

Thanks to the generosity of thousands of donors and various partners throughout Canada, the CRS has distributed over \$355 million in research grants and scholarships over the past 75 years; a testament to its impact on cancer research and ultimately on patients diagnosed with the disease and their families.

Our values

•**DETERMINATION**• Since 1945, the CRS has worked tirelessly toward one goal: outsmart cancer. •**PASSION**• The CRS works with conviction, discipline and determination to help Canadian researchers find ways to outsmart cancer. •**INTEGRITY**• The CRS respects and protects the interests of its donors by using the funds entrusted to it efficiently and responsibly, according to strict rules of governance. •**INNOVATION**• The CRS supports innovative projects involving creativity and original ideas, because it is through research that the solutions to cancer will be discovered. •**EXCELLENCE**• Guided by the highest standards and an uncompromising commitment, the CRS aims to exceed expectations in research. •**ACCOUNTABILITY AND GOVERNANCE**• Donor accountability goes hand in hand with our mission. Without the generosity of our donors, we could not carry out our mission of financing cancer research. As such, we have made it a core principle to ensure that donor dollars are allocated efficiently and effectively.

Board of Directors

Our team is fortunate to count on the support and commitment of several members on our Board of Directors, whose professional experience and devotion to the cause of cancer research are exceptional.

We are so grateful for their commitment and would like to highlight the appointment of Mr. Christian M. Paupe as Chair of the Board of Directors in December of 2021. Since he took office, Mr. Paupe has provided a vision and invaluable support for the entire management team.

We must also thank Mr. François Painchaud for his mandate as Chair of the Board of Directors between 2019 and 2021. He was a constant source of support and we are thankful for his valuable contribution to the CRS. Mr. Painchaud continues to serve as a Director of the CRS.

During this past year, Mr. Peter Clair and Mr. Carson Loh joined the CRS Board. We would like to offer them a warm welcome to the team.

As part of a continuous improvement process, the members of the management team and the Board of Directors took part in two governance training sessions offered by the Institute for Governance.



Christian M. Paupe,
Chairman of the Board
Corporate Director



Heidi Lange, CRHA
Vice-President and Secretary
Associate, Richter



Marie Valcourt, CPA, CA
Treasurer
Partner KPMG LLP

Directors



Kristell Baune
Manager, Business Analysis Telus Health



Peter Clair
Director and Market Lead, National Accounts, Québec, Scotiabank



Ghassan Deko
President and Chief Executive Officer, RCAP Leasing Inc



Benoît Durocher
Executive Vice-President & Chief Economic Strategist Addenda Capital Inc.



Carson Loh
Regional Vice President, North Shore and Tri-Cities Market RBC Royal Bank (British Columbia)



Peter McCarthy
President & CEO, BMO Insurance



Sean O'Brien
Executive Vice-President, Wealth Management, iA Financial Group



François Painchaud
Lawyer and Partner, ROBIC



Joanna Wilson
Executive Vice President and National Practice Lead, Health Edelman



George Zogopoulos, MD, PhD, FRCS(C), FACS
Associate Professor of Surgery and Oncology
McGill University HepatoPancreatoBiliary and Transplant Surgery McGill University Health Center

Research

Funding cancer
Research is
at the heart
of our mission



Supporting Cancer Research: Impacting the Life of Many

The Cancer Research Society is a leader in raising and dispatching funds to support cancer research in Canada to help prevent, detect, and treat the disease.

We do this by ensuring that every single contribution from our donors is allocated towards this goal. It may be hard sometimes for the donors to fully appreciate how their donations are contributing towards the bigger picture, given the protracted timelines for conducting research and the number of steps needed to ultimately demonstrate an impact for patients.

Scientific research is necessary to advance our understanding of a natural process, including cancer. It is a very rigorous and lengthy endeavour based on observation, hypothesis formulation and testing via specifically designed experiments. The experiments ultimately support or invalidate the hypothesis, often in an iterative loop. There is no winning or losing in science, and there is no worthless research, as every single experiment contributes to increasing our knowledge in a specific field: in our case, cancer.

The knowledge that inevitably comes from any scientific finding (positive or negative) is a fundamental piece of the puzzle that brings us closer to a solution. Our promise to both our donors and our grant recipients is that we will only support innovative, high-quality research projects with real potential for advancing the cancer field.

This section reflects on what impact means to us and how the sustained generosity and commitment of our donors have helped us reach and surpass our goals, with 2021 being an exceptional year and this despite the pandemic.



Covering the Cancer Research Spectrum

The Cancer Research Society believes in a comprehensive approach to the solution by funding the whole research spectrum from fundamental, to translational to clinical.

Fundamental Research

The purpose of fundamental research is to understand how natural systems work. While this exploratory quest is essential to advancing our knowledge, it is often difficult to demonstrate direct and immediate impact for patients. However, without fundamental research on cancer, every great cure, invention and scientific breakthrough would not be possible. Fundamental research sets the foundation for understanding human biology and the molecular mechanisms underlying the insurgence of cancer.

Translational Research

This type of research studies the applicability of what has been discovered in fundamental research so that the achievements can be “translated” into humans. Even in this case, results do not directly provide a cure for the disease, but without translational research, it would be impossible to bring any new approach to prevent cancer, new treatment or drug to the market.

Clinical Research

Clinical research is patient-oriented medical research involving the participation of volunteers. Clinical trials are expensive to set up, strictly regulated and often may take several years to demonstrate a significant impact on patients. Before a new treatment and drug can be carried forward to this stage, it must show real potential, and in many cases, some clinical trial drugs never make it to the market.

Supporting the Scientific Community

The progress of cancer research depends on the availability of sustainable funding to finance the best scientific minds of our times. For over 75 years, the Cancer Research Society has provided financial support to researchers at different stages of their career.


Next year, we are expanding our support with the launch of a new scholarship program for graduate students.



Operating Grants

The annual Operating Grants Competition is the principal means by which CRS fulfills its mission to support fundamental and early translational cancer research on all types of cancer, ultimately contributing to advances in the prevention, detection and treatment of this disease. Researchers are encouraged to apply at all stages of their career, from young investigators to established researchers.

These grants of \$120,000 over two years play an important role in the Canadian cancer ecosystem, enabling researchers to test their hypotheses and provide new directions to cancer research.



The Cancer Research Society broke its record for the greatest number of operating grants ever awarded in a given year, with 80 grants in 2021, up from 67 in 2020.

Scholarship for the Next Generation of Scientists

The annual Scholarship for the Next Generation of Scientists Competition closes the gap between our new Graduate Student Scholarship and the Operating Grants Programs.

Unique in Canada, this award of \$170,000 over three years offers bridge financing between postdoctoral work and an initial faculty position.

This opportunity is extremely valuable as it represents a launch pad for the most talented researchers to gradually and effectively establish their career in a recognized Canadian university or qualified institution.

The Canadian Cancer Research Alliance, an alliance of organizations that collaborate to promote partnerships among cancer research funders and the development of research priorities in Canada, recognized the unicity of the Scholarship for the Next Generation of Scientists Competition in their recently published report, "Fifteen Years of Investment in Cancer Research, 2005–2019":

"There has been much written in the past few years about the precarious position of postdocs, often considered to be the most valuable members of research laboratories, and this has been exacerbated by the pandemic. CRS's two-pronged Scholarships for the Next Generation of Scientists is an innovative mechanism to address this issue."

– Canadian Cancer Research Alliance, 15-Year Report


Graduate Student Scholarship

At present, there are very few targeted scholarships to support Canadian doctoral students conducting cancer research. Furthermore, graduate student grants for scientific research are also rare except for a few government-funded ones. It was recently highlighted in the news that current doctoral students' stipends fall below the poverty line, including through an [open letter to the federal government](#) signed by thousands of Canadian researchers.

The Cancer Research Society has answered the call and is launching a new Graduate Student Scholarship program in early 2023 that will provide doctoral students the opportunity to apply for a two-year scholarship worth \$70,000 to conduct their cancer research project at a Canadian university or accredited institution.

Andy and Léna Chabot Scholarship for Undergraduate Students

The Cancer Research Society is proud to continue its collaboration with its former President and Chief Executive Officer Andy Chabot. As an enthusiastic supporter of our cause and as a cancer survivor himself, together with his daughter Léna, they created the Andy and Léna Chabot Fund. Thanks to their initial financial contribution, this fund allows selected undergraduate students to pursue a four-month internship in a CRS-funded research laboratory. Since 2018, 4 students received this scholarship.



Peer-Review Process

Our goal is to ensure that, among the hundreds of applications the Cancer Research Society receives every year, only the most promising, innovative and thoroughly presented ideas are funded.

For each competition launched, we recruit cancer research experts, including scientists and doctors to assess the scientific quality, originality, feasibility, and the projects' potential impact. This peer-review process is widely adopted in the scientific community and ensures scientific excellence and rigour.

For the 2021 Operating Grants' competition, 85 experts participated in lengthy meetings to discuss and select the 80 best proposals. In addition, 10 reviewers were part of the committees to select this year's Scholarship for the Next Generation of Scientists awardees.

The CRS panel meetings are a great opportunity for the reviewers to stay up to date on the latest cutting-edge cancer research carried out in Canada, while networking and providing mentorship for the youngest investigators on the panel. Our review process is a source of great pride for CRS.

"Having participated in several peer-review committees, I particularly enjoy those organized by the Cancer Research Society for their sense of camaraderie and collaborative spirit.

At the end of the process, I leave knowing that the best projects were selected and will receive funding."

– Quote from one of our panel members

Leveraging our Impact

Over the past several years, the Cancer Research Society has made a concerted effort to work collaboratively and effectively with other organizations focused on supporting cancer research. This strategy has been quite successful and has enabled us to leverage the donations and fund more research.

In 2021, CRS successfully launched 2 new competitions on targeted cancers with strategic partners:

- **The Cancer Research Society and Ovarian Cancer Canada jointly invested \$2.25 million** in ovarian cancer funding 10 translational research projects.
- **The Cancer Research Society and the Quebec Breast Cancer Foundation jointly invested \$1 million** to fund 2 translational research projects in metastatic breast cancer.

CRS also participated in a multi-partner initiative in primary cancer prevention:

- **The Cancer Research Society, the Canadian Cancer Society and the Canadian Institute of Health Research—Institute of Cancer Research along with six other organizations jointly invested \$5.4 million** in cancer prevention funding 28 research projects. The CRS co-funded 4 cancer prevention research projects.

The exceptional success of our Operating Grant Competition in 2021 could not have been attained without the contributions of our valued partners, namely the Canadian Institutes of Health Research—Institute of Cancer Research, Canadian Institutes of Health Research Institute of Musculoskeletal Health and Arthritis, Cure Foundation, Leukemia & Lymphoma Society of Canada, Ovarian Cancer Canada and Quebec Breast Cancer Foundation who collectively co-financed 35 of the 80 Operating Grants awarded.

Thanks to an increased focus on strategic partnerships, the Cancer Research Society was able to double the number of grant competitions it managed and fund a historical record number of 104 new projects in 2021.

CRS is proud to be seen as a leader in leveraging research investments to make the best use of donors' contributions.

“Charities have increasingly looked at partnerships with others to leverage their investments, with the Cancer Research Society (CRS) leading the way on this front and enabling smaller-sized charities to fund mandate-aligned research.”

– Canadian Cancer Research Alliance,
15-Year Report

Thank you to our Partners

The Cancer Research Society would like to highlight the invaluable contributions made by various organizations which co-fund new research projects and funds created thanks to the generosity of major donors whose families have been affected by cancer. Our heartfelt thanks for contributing to our mission.

Alberta Health
BC Cancer Foundation
BMO Financial Group
Canadian Cancer Society
Canadian Institutes of Health Research—
Institute of Cancer Research
Canadian Institutes of Health Research—
Institute of Indigenous Peoples' Health
Canadian Institutes of Health Research—
Institute of Musculoskeletal Health and
Arthritis
Canadian VHL Alliance
Cure Foundation
Génomique Québec
Leukemia & Lymphoma Society of Canada
Ovarian Cancer Canada
Quebec Breast Cancer Foundation
.....
Andy and Léna Chabot Fund
Ann Matyas Memorial Fund
Aristotle Fund
Cancer Research Society's Environment-
Cancer™ Fund, funded in part by
Read for the Cure
Charlotte Légaré Memorial Fund
Fondation Bergeron-Jetté
Herbert J. Davies Memorial Fund
Katherine Campbell MacDonald Memorial
Fund
Steven E and Scott Drabin Research Fund
Succession Helen Lenore Bailey

Impactful Results

Although numbers* are far from being the only metric to define impact, Cancer Research Society grants and scholarships awarded between 2016-2020 resulted in:



* 2021: data not yet available

2021–2022 Record Year

In 2021–2022, the Cancer Research Society funded a historical record number of research projects including scholarships despite the COVID-19 pandemic.

Number of projects CRS funded in a given year

	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022
Number of projects	167	170	164	157	181

Competitions and Initiatives

	2021-2022
Operating Grants	80
Scholarships for the Next Generation of Scientists	4
Metastatic Breast Cancer competition	2
Ovarian Cancer competition	10
Primary Cancer Prevention initiative	4
UpCycle drug repurposing	2
Clinical Trials	2
Ongoing grants and scholarships	77
Total	181

Investments for Prevention, Detection & Treatment

Impact	2020-2021	2021-2022
Prevention	\$2,500,000	\$2,345,000
Detection	\$620,000	\$1,970,000
Treatment	\$6,700,000	\$8,145,000
Total	\$9,820,000	\$12,460,000

A focus on researchers

For the researchers who receive financial support from the Cancer Research Society, the impact is immense. A grant is essential for pursuing their project, both in terms of the scientific breakthroughs achieved over time and allowing them to continue their careers at Canadian research institutions.



“I look forward to a future where metastatic cancer is a treatable disease thanks to the knowledge acquired from cancer research.”

Yvonne Myal, PhD

Professor, University of Manitoba

2021 Operating Grant recipient, funded in partnership with the Canadian Institutes of Health Research—Institute of Cancer Research

Triple negative breast cancer is a type of breast cancer with the highest mortality rate. As part of her research project, Dr. Myal aims to better understand the mechanism of pulmonary metastases with the ultimate goal of developing new therapeutic strategies to improve life expectancy and quality of life for women diagnosed with aggressive and difficult to treat breast cancers.



“[Soon after starting my research career] I learned that my uncle had pancreatic cancer. He died a few months later. I was in shock. Never had I been so close to cancer. [As a consequence] I made up my mind to move my career in the direction of cancer research.”

Nathalie Rivard, PhD

Professor and Vice-dean of Graduate studies, Research and Innovation, Sherbrooke University

2021 Operating Grant recipient funded by the Cancer Research Society

Colorectal cancer is a leading cause of cancer-related deaths in Canada both for men and women. If detected early, this cancer is preventable in up to 90% of cases, but currently nearly half of the diagnosed patients find out too late. It is therefore important to develop new screening methods. This study focuses on understanding the molecular mechanisms behind the insurgence of colorectal cancer with the long-term goal of discovering a new genetic biomarker that could improve early detection or represent a novel therapeutic target.



“Patient-derived tumour models have considerable potential to reveal key insights into the biology of cancer progression and, by doing so, to enable better selection of personalized treatments.”

Gregor Reid, PhD

Associate Professor, University of British Columbia

2021 Operating Grant recipient funded by the Cancer Research Society

The majority of **children with acute lymphoblastic leukemia** achieve a first remission, but the recurrence of the disease remains a significant cause of mortality. With the goal of reducing relapse, this research is at a critical stage to identify relapse-driving cells early on. These cells are present after the first round of therapy and are a strong indicator of future relapse; however, they are in very low numbers, their biology is poorly understood and, at present, they cannot be targeted effectively. Based on early promising results, this study will provide a novel platform to investigate these cells, eventually contributing to the development of better risk-assessment and therapies.



“Thank you for this instrumental support at this early, critical state of my career. Your donations allow me to work towards a better future for pancreatic cancer patients.”

Barbara Grünwald, PhD

Assistant Scientist, Princess Margaret Cancer Centre

2021 Scholarship for the Next Generation of Scientists recipient funded in partnership with BMO

“**Pancreatic cancer** is a difficult nut to crack because it has a lot of non-cancer cells present in the tumour that help the tumour and support it in many different ways.” By studying the tumour microenvironment and the surrounding normal cells, Barbara and her team wish to better understand how these interactions promote tumour aggressiveness and therapy resistance. Altering these interactions could lead to promising new therapeutic solutions.

Special mention

In recognition of his pioneering work, Pieter Cullis was appointed Officer of the Order of Canada in 2021 and was co-recipient of 4 additional prestigious awards: the 2021 Prince Mahidol Award, the 2021 VinFuture Grand Prize, the 2022 Tang Prize in Biopharmaceutical Science, and the 2022 Canada Gairdner International Award.



Pieter Cullis, PhD

Professor, University of British Columbia

2012 Operating Grant recipient funded by
Cancer Research Society

While the immediate impact of fundamental research is often difficult to estimate on a larger scale, some stories are truly unique. This is the case of the research of Pieter Cullis, a past Cancer Research Society grantee.

His initial research focused on tackling the problem of delivery of cancer drugs specifically to the tumour site and ultimately resulted in the approval of two drugs used to treat cancer patients. More recently, Professor Cullis studied how the drug delivery system he developed could be used in conjunction with mRNA vaccines. With the resurgence of COVID-19, his research culminated in a collaboration with Pfizer/BioNTech for the development of their vaccine against the virus, which has contributed to saving millions of lives.

The Cancer Research Society congratulates Pieter Cullis for his outstanding contribution to the advancement of biomedical research and cancer drugs and for his mentorship of the next generation of scientists and entrepreneurs.

Fundraising and mobilization

Every year, we organize campaigns and events that bring together committed donors to support our mission

Once again, the themes of these events generated significant interest and had a rallying effect. The events would not have been possible without the profound engagement of the members of various organizing committees. We offer them our heartfelt thanks for donating their time to cancer research.





Urban BBQ A record-breaking edition

\$625,000

This 8th edition of the renowned Urban BBQ, presented by the RBC Royal Bank, broke a historical record. This summertime get-together that welcomes the Montreal area business community raised \$625,000, a record amount for a CRS fundraising event thanks to the roughly 900 guests and the several additional donations made that day.

The event was remarkable again this year, with the presence of Ricardo Larrivée, ambassador of the Urban BBQ, André Robitaille, CRS spokesperson, as well as the exceptional meal prepared by reputed chef Marc-André Jetté, from Hoogan and Beaufort.

Its success is the result of the exceptional involvement of Ms. Nadine Renaud-Tinker, Regional President - Quebec Headquarters, RBC Royal Bank, the event's honorary President, and Mr. Jean-François Prince, Regional Vice-President, Business Financial Services - Quebec Headquarters, RBC Royal Bank and Chair of the Patrons of Honour Committee, as well as all of the members of this group who invested their time for months to fight cancer through research.



CRS Classic

\$200,000

For a 27th year, the Cyclo-Golf Classic (cycling, golf and walking), presented by Scotia Bank and BMO Insurance brought together many sports enthusiasts in Montreal, Sherbrooke (in partnership with the Université de Sherbrooke's Cancer Research Institute) and, for the very first time in Quebec City, with the support of the CHU de Québec's research centre and the Université de Laval's Faculty of Medicine. Participants raised funds on their own or as part of a team.

CRS Challenge in the Magdalen Islands

\$122,000

A group of participants visited the Magdalen Islands in September of 2021 to take up a CRS Challenge, the first since the onset of the COVID-19 pandemic. Participants, who had previously raised funds, had an opportunity to embark on a major hiking challenge to benefit the CRS. Stéphane Rousseau, the Cancer Research Society's spokesperson for the past eleven years, took part in the challenge as a way of bookending and celebrating his active involvement.



Contact Amérique
Voyage



Accords Célestes Evening

\$190,000

This 4th edition of the Accords Célestes evening, hosted by André Robitaille, CRS spokesperson, was held in person at the acclaimed Le Mouso restaurant for some, and from the comfort of home for others. Guests enjoyed a gourmet menu presented by renowned chef Antonin Mousseau-Rivard, perfectly paired with wines from La Maison Jean Loron, followed by an unforgettable musical performance by singer-songwriter Michel Rivard.



Read for the Cure

\$120,000

Presented by Penguin Random House Canada, the events surrounding the 14th edition of Read for the Cure were held virtually for a second year in an effort to mitigate constraints associated with the COVID-19 pandemic. These evenings brought together literary enthusiasts from across Canada to benefit the Cancer Research Society's Environment-Cancer™ Fund which supports researchers studying environmental causes of cancer and the preventive measures to ensure that fewer Canadians are affected.



Cancer Heroes Campaign

\$280,000

For a 2nd year in a row, this campaign showcased cancer heroes, namely people currently fighting cancer and cancer survivors. Heroes are also the caregivers, the doctors, nurses and researchers who focus on research to outsmart cancer and the donors, without whom it would not be possible to contribute to preventing, detecting and treating this disease.



World Cancer Day

\$20,000

To highlight World Cancer Day, which takes place each year on February 4th, a digital campaign was organized to remind people of the importance of the cause which remains the disease with the highest mortality rate in the country. In fact, two in five Canadians will receive a cancer diagnosis in their lifetime. That means that most of us will be directly or indirectly affected by the disease.



International Women's Rights Day

\$19,000

We launched a digital campaign on March 8, 2022, to mark International Women's Rights Day, specifically to highlight women's contributions to cancer research and their achievements. The funds raised allowed two undergraduate students to undertake a training internship with researchers who ranked in the top tier of our annual operating grant competition. This initiative will help initiate female students to the research sector, and in doing so support established researchers as they will benefit from the support of the next generation of scientists.



The "We need you!" campaign

\$115,000

To mark World Health Day on April 7th, 2022, a new digital campaign under the theme "We need you" was launched to generate popular awareness about the importance of cancer research, as well as to raise funds that will make it possible to fund several cutting-edge research projects on this disease.

Many ambassadors were highlighted during this campaign, including researchers and survivors, all stating research is the key to outsmarting cancer.



“This summer, I’m donating to cancer research” campaign

\$46,000

For this campaign, which was launched mid-summer, the CRS team encouraged donors to make an online donation equivalent to the cost of little indulgences that we offer ourselves from time to time: a second latté, a meal out at a restaurant, a pair of sneakers, etc.

With this fun way of doing things, you could match a purchase amount with an equivalent donation to the Cancer Research Society.



The Cancer Research Society’s BMO Mastercard

Thanks to a long-standing partnership with BMO, you can support the CRS by getting this Mastercard. For each purchase made using the Cancer Research Society’s BMO Mastercard, the BMO Financial Group will make a contribution to us.

This partnership has allowed us to distribute over **two million dollars** to fund cutting edge cancer research. We would like to thank all cardholders who have chosen this means of supporting our mission.

Citizen Initiatives

Each year, people organize activities and fundraisers which will help raise funds and directly support our mission.

We are so grateful for their initiatives and their support. Here are some of the community-led events that marked 2021-2022.

- Journée de la Marche du Rêve
- Ski for a Cure - Rob Lutterman
- Launch of the movie Aline by Maison 4:3 and Caramel films
- Traversée du Québec – Denis Dionne
- Montreal’s 21k fundraising challenge
- The Saint-Lambert Games
- Toronto Waterfront Marathon Fundraising Challenge
- Bar Pincoart – Grill sales
- Annual Stuart Roebuck Golf Classic
- The Félix Hardy gold and volleyball tournament
- BBQ Boucanalex – Ste-Julie Motorcross Championship
- South Ontario Chapter Charity Golf Tournament
- Vancouver Half Marathon Fundraising Challenge
- Andrea Wenckebach running
- Step up For a Cure – Massey-Vanier
- Douglas Shapiro Golf Tournament
- Cruise for the Cure
- Red Hot & Blue Rockabilly Weekend-Silent auction
- Eliot Morin maple product sales
- Dépanneur Bossuet Piggybank
- Dominique Carpentier Fundraiser
- Café Wiltor
- Comic for the Cure
- Verger Pommalbonne – candle sales
- BMR fundraiser – Matco branch

Donors

RegaRdless
of the amount,
each donation
advances cancer
ReseaRch

We are grateful for every donation we receive, as they enable us to carry out our mission.



Monthly

This type of donation helps the CRS by providing consistent, reliable support. This allows the CRS to plan in advance, thus having a greater impact to outsmart cancer. It is an easy and affordable option which offers the flexibility of changing your donation amount at any time.

Life Insurance

This type of donation is a simple and flexible way to make a significant impact at a relatively small cost. It allows the donation to be paid in annual instalments (the policy premiums) and offers a receipt for a tax credit.

Endowment Fund

An endowment fund ensures that the donor's commitment is preserved over the long term and that the funds will be directed to the type of cancer that corresponds to the donor's choice and priority. An endowment can be in the donor's name or in the name of someone they wish to honour.

Types of donations

Whether spontaneous or planned, there are so many ways to support the cause.

Gift of Securities

Tax exemptions are available for donations of eligible securities such as stocks, bonds, mutual funds, drafts, futures or any other publicly traded security.

Gift of Goods

A gift of goods, also known as an "in kind" donation refers to gifts of tangible property, such as real estate, special collections, cultural good and works of art accompanied by certificates of fair market value.

A gift of goods can be sold or retained and used by the CRS. The tax receipt is issued for fair market value of the gift. Please note that these donations require CRS approval before being accepted.

RRSP or a RRIF

Another way to make a donation to the CRS at the time of a person's passing is to give a portion or all of the securities held in a Registered Retirement Savings Plan (RRSP) or a Registered Retirement Income Fund (RRIF). These retirement funds are among the most heavily taxed assets. The CRS will issue a tax receipt for the amount transferred to the estate.

Planned Giving

Each year generous people make a hopeful gesture by making a legacy gift in their will to support cancer research. Whatever the amount of the bequest, it provides important support for the CRS to carry out its mission.

This year, the CRS received 50 legacy gifts, totalling close to \$1 million.

Please do not hesitate to contact us if you would like additional information on the different donation options. Working alongside your financial or legal advisor, we can find the option that best suits your philanthropic objectives and takes your personal and financial situation into account.

For more information contact us **1 866 343-2262** or info@src-crs.ca.

We would like to thank every person who left a gift in their will that will significantly impact research.

Allan Webster Realmount Foundation

Aylard, Audrey

Bailey, Helen Lenore

Barwick, Arthur O.

Bissonnette, Andrée

Bouchard, Pauline

Blackhall, Linda Gael

Champagne, Nicole

Choi, Yun Yan

Côté, Gérard

Decock, Marcel

Dalton, Adele Maria Jutta

Drouin, Françoise

Duong, Mai Hang

Groulx, Cécile

Hayhurst, Shirley Alice

Hicks, Vivien Evelyn

Jones, Joan

Laframboise, Rita

Lareau Harlick, Marie-Paule

Macdonald Anderson, Archibald

Macgregor, Betty Helen

Maud And Christina Duncan Charitable Foundation

Mercier, Joseph Albert Pierre

Mongrain Ferguson, Muriel

Moore, Mary

Norma Mclean Charitable Fund

Pépin, Cécile

Rahm, Gertude Lisette

Richardson, Hazel Jean

Saucier, Marc

Stinchcombe, Ronald Keith

Swan, Edith M.

Vethamany, Shama K.

Wain, Elsa Margaret Ann

Wong Aie, Edward



Donor portraits

The Gosselin Family Foundation: improving people's lives one donation at a time



“Supporting all types of cancer is very significant to us. Each research project is important and promising; that is why we need to offer them the necessary financial support.”

– Léon Gosselin

We are grateful for the support from each of our donors. They all come from different horizons and with their own personal motivations, but they all share a desire to contribute to outsmarting cancer. That is the case for Diane and Léon Gosselin, who made a substantial donation to the CRS this year- one that will allow us to fund a research project on lung cancer.

They are truly an inspiring couple, in part due to the success of their company, Axcan Pharma, as they had a positive impact within the medical ecosystem, but more importantly because of their immense generosity. They have been very successful in business and now want to pay it forward. Among other things choosing to sell their business has enabled them to establish their foundation, which has supported several organizations for over ten years, providing invaluable financial support.

For them, it is particularly important to support cancer research: ***“The reality is that we can be in perfect health and lead a healthy lifestyle, but we are all at risk of developing cancer or having a loved one diagnosed with the disease.”***

Indeed, Mr. and Mrs. Gosselin can personally testify to the disease's impact in their own lives as Mrs. Gosselin faced cancer herself in the past decade and Mr. Gosselin's sister sadly passed away from the disease. They can also attest to the impact of research; Mr. Gosselin has annual tests as a preventive measure. He is grateful for the progress made through research, including prevention.

Mr. Gosselin's testimony can only encourage us to make a donation to cancer research: ***“researchers work tirelessly to extend and improve people's quality of life and its extremely gratifying to make a donation that allows them to do that important work.”***

Donors

We are so grateful for the support of organizations who believe in our mission and make a financial contribution. We thank them for this support and for helping raise awareness for the cause within their organizations.

\$100,000 and up

BMO Bank of Montreal / BMO Mastercard Affinity Program / BMO Insurance / BMO Financial Group / BMO Global Assets Management
Diane and Léon Gosselin Family Foundation
Gift Funds Canada
Penguin Random House Canada

\$50,000 to \$99,99

Benevity
Innovairre Studios Inc.

\$25,000 to \$49,999

3515877 Canada Inc.
Bergeron-Jetté Foundation
CN Employees' and Pensioners' Community Fund
Econo-Malls Management
Industrial Alliance – Financial Group

PH&N Investment Counsel / RBC Wealth Management

RBC Royal Bank / RBC Wealth Management / RBC Dominion Securities Inc. / RBC Capital Markets

Sandra and Alain Bouchard Foundation
Scotia Bank

\$10,000 to \$24,999

Air Canada
Alre Properties
Brain Finance
Cons Properties Management Inc.
Crowe Bessner Gallay Kreisman
Desjardins Business / Desjardins Group / Desjardins Philanthropic Funds – Jacques Marchand Fund
Dunton Rainville
Elad Canada Realty Inc.
Geloso Group

Italian Chamber of Commerce in Canada
Ivanhoé Cambridge Inc.
Markham Waterloo Mennonite Conference
Maud and Christina Duncan Charitable Foundation
Montreal Port Authority
Novacap
NU-B Inc.
Perma Financial Services Inc.
Pyrogenesis
Quantum Bike
Robic S.E.N.C.R.L./LLP
Saputo Inc.
SFL Wealth Management
SNC-Lavalin
Société des alcools du Québec
South Saskatchewan Community Foundation
Stokes

Strategic Charitable Giving Foundation
Sun Life
TD Commercial Banking Services / TD Asset Management / TD Securities
The Ken and Roma Lett Foundation
Unifood Inc.

\$5,000 to \$9,999

0956267 B.C UNLIMITED LIABILITY COMPANY

10162884 Canada Inc.
(A.M. Breakfast and Lunch)

144781 Canada Inc.

Abundance Canada

Accord Financial

Addenda Capital

Apollo Microwaves

Au Vieux Duluth Restaurants Inc.

Barrette Bois Inc.

Bédard Resources Inc.

Benny & Co.

BlueShore Financial

Bombardier

Borden Ladner Gervais LLP

Broccolini Construction Inc.

Broue Alliance Inc. / Geloso Group

C.M. Equipment Inc.

Canderel Management Inc.

Cedarom Canada

CGC Charitable Foundation
Chicago Title Insurance Company
Cogir Real Estate
Congregation of the Marist Sisters
Corporation BCF Inc.

Davies Ward Phillips & Vineberg

Deterco Builders Inc.

DLVRD Logistics

Econolunettes

Ernst & Young

Fidelity Investments Canada ULC

G2S TOBEQ Inc.

Genatec Inc.

Germain Larivière

Gilbert Séguin Guilbault Avocats

Gowling WLG (Canada) LLP

Groupe Deschênes Inc. (Espace Plomberium)

Groupe Mach

Groupe Montoni Division Construction Inc.

Habitat l'Atelier Inc.

IMKT Direct Solutions Corp.

Immobilier Carbonleo Inc.

J. R. Armstrong Family Foundation

Jolina Capital Inc.

Kelson Financial

KPMG MSLP

KRB Avocats (Karambatsos Avocats Inc.)

Lagoon Seafood Inc.
Laurentide Controls
Le Groupe Maurice
Levy Salis
LSR GesDev
Majoca Investments
Métro Richelieu Inc.
Miller Thomson
Mobilia
National Public Relations Firm
NeurodidAct inc.
Norton Rose Fulbright
Oaklins Canada
Popote Roulante Saint-Ferdinand
Private Giving Foundation
Raymond Chabot Grant Thornton
Second Cup
Soprema Canada Inc.
Spiegel Sohmer Inc.
Stingray Digital Group Inc.
The Kent Group
Tidan Inc.
TKNL Inc.
Triad Management Services Inc.
Trudel Immeubles Inc.
Wellington Laboratories Inc.

\$1,000 to \$4,999

100386 Ontario Limited
 1832 Asset Management L.P.
 497505 Ontario Inc.
 9122 2182 Québec Inc.
 9314-6512 Québec Inc.
 94074507 Québec Inc. (Marché Public 440)
 9825754 Canada Inc. - Ipso Facto
 Investissement Immobilier
 ABC Pest Control Services Inc.
 ABMS Évaluateurs Agréés – Chartered
 Appraisers
 Accord Expositions Inc.
 Action Construction Infrastructure Inc.
 Addisplay
 AEDN
 AgroFusion
 Aliments Pimentel Inc.
 All Sides Crating Inc.
 Alton Holdings inc.
 Altus Group
 Amgen Canada
 Backstage Commerce Inc.
 Bastix Souvenirs
 Beaulieu Vision Care
 Bellemont Powell
 Benefaction Foundation

BentallGreenOak
 Block Bindings & Interlinings Ltd.
 Boily Handfield
 Brière Family Foundation
 Brigil
 Bryan Ventures Incorporated
 C.I.F Properties
 Cabinet d'Orthodontie Catherine Jomphe
 Calgary Foundation
 Canada Hydraulique Équipement
 Caprea Experts Immobilier
 Castel Development
 Cercle Filles d'Isabelle #715
 Cerco Cable
 Chabot Médiateurs Avocats
 Château Taillefer Lafon
 Chevaliers de Colomb Conseil 2802
 Chiasson Gauvreau Inc.
 CO7 Technologies
 Collection Équinoxe
 Community Foundation of Ottawa
 Complexes Funéraires Yves Légaré
 Construction CPB Inc.
 Construction R. Brossoit
 Copper Core Limited
 Costco Canada
 Crofton Moore

D.B. Crook Accounting Prof. Corp.
 David Forest Financial Group
 Delmar International Inc.
 Demers Beaulne S.E.N.C.R.L.
 Denise and Robert Gibelleau Foundation
 Dentons Canada
 DEVAMC Canada Inc. (Allô! Mon Coco)
 Développements Nelligan
 Divco
 Dorel
 Dr Xuan Linh Chi Ho. Optométriste Inc.
 Effix
 Enerquin
 Ercon Welding Inc.
 Excavations Jacques Germain et fils Inc.
 Farhat Realty
 Fasken Martineau Dumoulin S.E.N.C.L., s.r.l.
 FCT Compagnie de Titres First Canadian
 Ltée.
 Federal Real Estate Group
 Fondation Aide à la Jeunesse
 Foundation of Greater Montreal
 Francis McKenzie Inc.
 Freedom International Brokerage Company
 Fromagerie Hamel
 Gardium Sécurité Inc.
 Gascon and Associates

Gerjotin Inc.
 Gestion Andre Valiquette Ltée.
 Gestion Bert Inc.
 Gestion David Proulx Inc.
 Gestion Denis Chicoine et Fils
 Gestion François Pilon Ltée.
 Gestion Gauthier Lépine Inc.
 Gestion Luc Rodrigue (2019) Inc.
 Gestion Michel Dubé Inc.
 Gestion Raymond Brodeur Inc.
 Gestion Rosaire G. Dubé Inc.
 GLT+ Inc.
 GPM en Œuvre
 Grenier Gagnon
 Griva-Pete Holdings Inc.
 Groupe Chagall
 Groupe Desgagnés Inc.
 Groupe Focus
 Groupe Lebel Inc.
 Gym FitForme
 Highlight Motor Freight Inc.
 Holand Leasing
 Innovo Pharma Inc.
 Invera Inc.
 Investissement Québec
 Isatis Services Afriques Inc.
 ITC

ITI International Inc.
 Jacques Forest Foundation
 Jarislowsky Fraser Ltée.
 JCB Construction Canada
 JRTech Solutions
 La Céleste
 La Corporation Cadillac Fairview Limitée
 L'Association des Familles Montambault
 Le Groupe Alfid Ltée.
 Le Groupe Charbonneau
 Les Aliments Lesters Limitée
 Les Augustines de la Miséricorde de Jésus
 Les Développements P.A.T.
 Les Emballages Carrousel Inc.
 Les Missionnaires Oblates de St-Boniface
 Les Plastiques Forget Inc.
 Les Soeurs de l'Assomption de la Sainte-Vierge
 L'Express du Midi Inc.
 Libertum Inc.
 Logistques Lyand Inc.
 Mackenzie Investments
 Maçonnerie GY
 Maison Adam
 Manulife Financial
 Matière (grise) Ressources Humaines Inc.
 MC Finance Inc.

McCarthy Tétrault S.E.N.C.R.L., s.r.l.
 Media de Caisses Enregistreuses Inc.
 Médicaments novateurs Canada
 Michoel and Sara Goldie Kleiner Charitable Trust
 Mistplay Inc.
 MNP
 Modextil
 Mondoux Confectionery Inc.
 MSC Mediterranean Shipping Company (Canada) Inc.
 MTL Développement Inc.
 My Tribute Gift Foundation
 Nam Polymers Inc.
 National Bank
 Nicola Wealth Private Giving Foundation
 Normandin Beaudry, Actuaire conseils Inc.
 Octantis - agence numérique
 OEC Overseas Express Consolidators Montreal Inc.
 Osler, Hoskin & Harcourt LLP
 Otera Capital Inc.
 Parade Leasing
 Patrick Morin Inc.
 Pavé Paysage Boisbriand
 Pennant Farming Co. Ltd.
 Pierre & Camille Dupuis (PC Dupuis)
 Pimco Canada Corp

Presse Café franchise Restaurant Inc.
 Procam Construction
 Productions IUZ Inc.
 Proxim - Succursale Saint-Jérôme
 PSB Boisjoli, LLP
 Québec International
 R.M. Specialty Cars Inc.
 Rachel Julien
 Ray A. Thompson Trucking Ltd.
 Réal and Chantal Mimeault Foundation
 Regal Poultry 2017
 Régulvar Inc.
 Renald Côté 2007 Inc.
 RGA
 Rose Hill Foods Inc.
 Roynat Capital
 Russell Investments
 S T Maçonnerie Inc.
 Sandalwood Managment
 Servantes de Notre-Dame-Reine-du-Clergé
 Services Financiers Luc Lauriault Inc.
 Servier Canada Inc.
 Shaker Franchiseur
 Shon Yee Benevolent Association of
 Canada-Calgary Branch
 Sisters of Providence of St. Vincent de Paul
 Société Professionnelle DL Inc.

Sœurs Missionnaires de Notre-Dame-
 des-Anges
 Soliman Corporation
 Solutions Avantages Collectifs Inc.
 Solutions Mapas Inc.
 Stageline Scène Mobile Inc.
 St-Pierre et Associés
 Supresseur 4S
 Suzanne and Jean-Robert Leclerc
 Foundation
 Télésystème Ltée.
 The Frontenac Foundation's
 Pierre Mantha Fund
 The Sahara Foundation
 The Shaw Corporation
 Trac-World Freight Services Inc.
 Trispec Communications Inc.
 United Way / Centraide of Ottawa
 United Way of Greater Toronto
 United Way of Kingston, Frontenac,
 Lennox & Addington
 Vancity Community Foundation
 Vancouver Foundation
 Wazo Furniture
 Wittenberg Construction Ltd.
 Wyalta Resources Ltd.
 Yale Properties

Financial Information

These **R**esults a**R**e a **R**eflection of ou**R** dono**R**s' and pa**R**tne**R**s' g**R**eat gene**R**osity, as well as the success of the st**R**ategic initiatives that have been implemented by the CRS team.

Financial information ending August 31, 2022, demonstrates healthy financial management. CRS's investments are governed by Jarislowsky, Fraser Limited, Global Investment Management's sustainable investing principles.

Summary of Revenues and Expenditures

on August 31, 2022

(in thousands of dollars)

\$23.8 million

Commitments of multi-year research programs extending into the future years

REVENUES	2022 Total	2021 Total
Annual campaigns	23,597	23,742
Major donations and planned giving	2,050	2,748
Benefit events and others	2,502	1,736
Partnerships – research contributions	2,007	1,486
Investment income, realized	2,310	2,602
Investment income, unrealized	(8,323)	3,958
Other revenues	3	400
	24,146	36,672
EXPENDITURES		
Annual campaigns	12,286	11,764
Major donations and planned giving	189	171
Benefit events and others	1,225	864
Administration	1,355	1,099
Amortization of real estate, equipment and software	60	64
	15,115	13,962
SURPLUS AVAILABLE FOR RESEARCH	9,031	22,710
“GRANTS AND FELLOWSHIPS (including related expenses)”	12,461	9,838
(SHORTFALL) EXCESS OF REVENUES OVER EXPENDITURES	(3,430)	12,872

Summary of Financial Situation

on August 31, 2022

(in thousands of dollars)

IMAGINE
CANADA

ASSETS	2022 Total	2021 Total
Cash	10,822	8,855
Accounts receivable	276	162
Prepaid expenses	294	244
Other current assets	108	85
	11,500	9,346
Investments	41,284	46,282
Fixed assets	275	324
	53,059	55,952
LIABILITIES		
Accounts payable and accrued liabilities	787	678
Deferred contributions – short term	1,246	236
	2,033	914
Deferred contributions	209	775
Lease inducement	91	108
	2,333	1,797
FUND BALANCES		
Allocated funds	6 626	5 977
General funds	44,100	48,178
	50,726	54,155
	53,059	55,952

Commitment to our donors

Every donation
is a token of
confidence in
our organization
and our
Researchers



Commitment to our donors

At the Cancer Research Society, we recognize that it is our privilege to be the recipients of generous gifts from our supporters. These donations allow us to fund the best cancer research in the country and it is because of that support that we are able to continue our efforts to outsmart cancer and save lives.

We have made the following pledge to our donors and partners:

- Your gifts will be used for the sole purpose of supporting our mission: funding research on all types of cancer to help prevent, detect, and treat this disease.
- We will strive to keep our cost of fundraising as low as possible while delivering the greatest impact.
- Information about your donation will be handled with respect and with confidentiality to the extent provided by law.
- You can be assured that our methods of fundraising are constantly reviewed, ethically-based, and minimize cost while maximizing impact.
- You will receive acknowledgment and recognition in a timely manner.
- If you have questions, comments, or feedback you can expect prompt, transparent, truthful, and forthright answers.

Thank you to all of our donors and partners who allow us to outsmart cancer.

Our Future Goals

The achievements of the Cancer Research Society are only possible thanks to the generosity of thousands of donors over the years. Even the smallest of donations contributes to the advancement of our understanding of the biology of cancer, that will one day add up to some life-changing discovery.

Science is constantly evolving in terms of increased number of collaborations and new technological advances, such as the use of precision medicine and artificial intelligence in cancer research.

The CRS is proud to help shape the future of the Canadian cancer research landscape by funding the most promising and cutting-edge projects.

In these evolving times, CRS is seen as a leader. By leveraging our efforts to better serve the scientific community, the future is bright and exciting, with CRS supporting some very innovative pediatric cancer projects and a commitment to invest more in early clinical trials.







Montreal

625 President-Kennedy Avenue, suite 402
Montreal, Quebec H3A 3S5

Ottawa

P.O. Box 4613, Station E
Ottawa, Ontario K1S 1P7

Telephone: 514 861-9227 • Toll free: 1 888 766-2262

info@src-crs.ca



CancerResearchSociety.ca

Charitable Registration No. 119153229RR001

ISSN 1920-8995 – Legal Deposit – Bibliothèque nationale du Québec, 2022